Patent intelligence · US
US 7687481
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
Cannabinoid receptor antagonists/inverse agonists useful for treating obesity
Patent details — US 7687481
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 30, 2010
- Expiration
- Mar 25, 2030
- Applicant
- Jenrin Discovery, LLC
- Claims
- 32
- CPC classes
- A61P, A61P1/04, A61P1/16, A61P11/00
Quick answer
US 7687481 (Cannabinoid receptor antagonists/inverse agonists useful for treating obesity) is held by Jenrin Discovery, LLC. Status: granted. Granted Mar 30, 2010. Expires Mar 25, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jenrin Discovery, LLC
- Grant date
- Expiration
- Claims
- 32
- CPC classes
- A61P, A61P1/04, A61P1/16, A61P11/00, A61P15/00, A61P19/02
More from Jenrin Discovery, LLC
Related pharmaceutical patents in our USPTO index.
-
US 12427173
Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
granted -
US 12428415
Matriptase 2 inhibitors and uses thereof
granted -
US 12421236
Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor
granted -
US 12420085
Synergistic therapies for inter vertebral disc degeneration
granted -
US 12421231
Azaindole derivatives and their use as ERK kinase inhibitors
granted -
US 12403069
Adapter for use in a planetary mixer
granted -
US 12398179
Nanomolar peptides and derivatives to differentially modulate ephrin receptors
granted -
US 12396924
Adapter for use in a planetary mixer
granted
Frequently asked questions
What is US patent 7687481?
US 7687481 (Cannabinoid receptor antagonists/inverse agonists useful for treating obesity) is held by Jenrin Discovery, LLC. Status: granted. Granted Mar 30, 2010. Expires Mar 25, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7687481?
Jenrin Discovery, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.
When does US 7687481 expire?
Our index shows an expiration date of Mar 25, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.